Business
SVN-SDN-14 PTSD - Positive pre-clinical results
SVN-SDN-14 PTSD - Positive pre-clinical results.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n12 August 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nSVN-SDN-14 PTSD Programme - Positive pre-clinical results with three high-performing candidates advancing to in vivo studies\nSolvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, today announces positive results from pre-clinical screening in its SVN-SDN-14 programme, identifying three high-performing candidates to advance into in vivo studies.\nThe SVN-SDN-14 series is a novel class of serotonin (\"SERT\"), dopamine (\"DAT\") and noradrenaline (\"NET\") modulators designed to enhance pro-social behaviour and improve therapeutic outcomes for people living with Post-Traumatic Stress Disorder (\"PTSD\"), which the Company estimates affects over 20 million people across UK, US, and main EU markets. By modulating neurochemical pathways associated with trust, empathy, and social bonding, these compounds aim to help patients rebuild interpersonal relationships, reduce social isolation, and engage more effectively in therapy.\nIn-vitro screening for SERT, DAT, and NET modulation activity identified three of six synthesised candidates with robust, balanced modulation profiles across all three neurotransmitter systems. These are precisely the mechanistic attributes the programme is targeting to deliver a new class of medicine for trauma-related mental health conditions such as PTSD.\nWhile the Company had previously anticipated selecting a single lead candidate at this stage, the positive performance of three candidates has delivered an optimal outcome - a strong, competitive shortlist with multiple best-in-class contenders. This outcome increases optionality, strengthens the dataset and enhances the probability of selecting a best-in-class candidate with strong commercial potential.\nThe three shortlisted candidates will now advance to the final stage of the current work package - in vivo preclinical s...